Source link : https://www.mondialnews.com/2026/04/20/lenz-therapeutics-advances-presbyopia-treatment-with-groundbreaking-vizz-marketing-application-in-the-uk/
LENZ Therapeutics has officially submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for its innovative drug VIZZ®. Designed to treat presbyopia, a common age-related condition that impairs near vision, VIZZ® represents a promising advancement in eye care. This regulatory milestone marks a significant step forward for LENZ Therapeutics as it seeks approval to bring the treatment to patients across the UK, potentially offering a new non-invasive option for millions affected by presbyopia.
LENZ Therapeutics Advances Presbyopia Treatment with VIZZ Submission to UK Regulatory Authority
LENZ Therapeutics has taken a significant step forward in expanding access to its innovative treatment for presbyopia by submitting a Marketing Authorization Application (MAA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This submission marks a crucial milestone in the company’s mission to address the growing need for effective, non-invasive solutions for age-related near vision decline. VIZZ®, LENZ’s proprietary eye drop formulation, aims to enhance visual performance and improve quality of life for millions of individuals coping with presbyopia across the United Kingdom.
The application includes comprehensive clinical data demonstrating VIZZ’s safety and efficacy, supported by a robust regulatory strategy designed to expedite review and approval. Key highlights of…
—-
Author : Miles Cooper
Publish date : 2026-04-20 18:39:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8